Join Actively Recruiting Research Studies
Discover ways to join new and ongoing clinical research studies. We are actively recruiting participants through the COPD Foundation for these research studies:
Smartwatch Monitoring of COPD Symptoms:
Research study for people with COPD who have had an exacerbation/flare up of their COPD in the last year that required treatment with antibiotics and/or prednisone.
- The purpose of this study is to identify risk factors that are predictive of COPD exacerbations. Participants will be asked to wear a smartwatch and answer a daily survey asking about their respiratory symptoms.
- Results from this study will help researchers develop a system to detect COPD exacerbations using smartwatches.
- This is a remote study; no clinic visits are required.
- Participants must have a smartphone.
Click below for additional information regarding participation:
BOSTON-1 & BOSTON-2
Study ID: NCT03657342 & NCT03656926
Condition: Bronchiolitis Obliterans Syndrome / Lung Transplant Rejection
Drug Name: Liposomal Cyclosporine A (L-CsA)
Trial Phase: Phase 3
Sponsor: Zambon SpA
Study Purpose: BOSTON-1 & BOSTON-2 are Phase III randomized, controlled clinical trials of L-CsA for the treatment of bronchiolitis obliterans syndrome in adults diagnosed with BOS following lung transplant. Patients will receive either L-CsA via the PARI Investigational eFlow® Device twice daily plus Standard of Care (SoC) treatment, or SoC alone, for a period of 48 weeks. All patients will be evaluated following completion of BOSTON-1 or BOSTON-2 to continue in an open-label extension trial of L-CsA. This study is called BOSTON-3.
More details can be found at clinicaltrials.gov or at the BOSTON study info website.
Contacts: Dr. Ferdinando Ceravolo, Global Clinical Lead - Ferdinando.Ceravolo@ZambonGroup.com
Mucus and mucus-related symptoms (sputum and phlegm production; chest congestion; cough) are some of the primary drivers leading to decreased quality of life in people with non-cystic fibrosis bronchiectasis (NCFBE). Renovion is conducting a clinical trial for people with NCFBE who are experiencing mucus symptoms as a significant component of their NCFBE diagnosis. The results of this study will enable a better understanding of the investigational product ARINA-1. ARINA-1 is a new mucolytic agent intended to decrease mucus viscosity and promote mucus clearance. The results of this study will aid in the development of the investigational product to improve quality of life in people with NCFBE. Renovion is collaborating with the COPD Foundation’s COPD360Net initiative to facilitate the success of this trial.